Kathleen Sereda Glaub has been appointed to Codexis' board of directors. Her 30-year career in leadership positions with drug development and technology companies is expected to bring strong company-building and business strategy experience to the Codexis board.
Glaub has recently been appointed as CEO of Afferent Pharmaceuticals, a clinical-stage biotechnology company that is developing treatments for respiratory and urologic disorders and chronic pain, where she has been a member of its board of directors since 2013. Prior to Afferent, Glaub held positions at Plexxikon, Cell Genesys, Genentech, and Intel.
